Business Monitor International


India Pharmaceuticals & Healthcare Report

Published 08 December 2014

  • 130 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
India Pharmaceuticals & Healthcare Report

BMI View:   The new government under Prime Minister Modi bodes well for the overall pharmaceutical sector. The proposed introduction of universal healthcare in 2015 coupled with small regulatory reform will help unlock the potential of the large Indian market.

Headline Expenditure Projections

Pharmaceuticals: INR904.0bn (USD15.4bn) in 2013 to INR1,021.8bn (USD17.0bn) in 2014; +13.0% in local currency terms and +10.36% in US dollar terms. 

Healthcare: INR4,640bn (USD79.2bn) in 2013 to INR5,179.9bn (USD86.3bn) in 2014; +11.6% in local currency terms and 9.0% in US dollar terms

Risk/Reward Index

India's Pharmaceutical Risk/Reward Index(RRI) score for Q414 is 53.0 out of the maximum 100, in our newly improved RRI system. The country scored above average for some indicators and sub-indicators including overall market expenditure, sector value growth, population growth. Nevertheless, it scored below regional average for most indicators under industry and country risks. Consequently with the moderate score, India is ranked tenth, behind New Zealand, out of the 19 key markets in Asia Pacific.

Key Trends And Developments

  • In November, India's National Health Assurance Mission is expected to cost an estimated INR1.6trn (USD26bn) over the coming four years, reports Reuters, citing additional secretary at the health ministry C.K. Mishra. Under the mission, all Indian citizens will receive free drugs and diagnostic treatments, together with insurance cover for the treatment of serious diseases. The proposed mission is expected to start in phases from April 2015 and will cover the entire population by March 2019, stated Mishra

  • In October, Indian drugmakers and public health activists warn that introducing changes to the country's patent laws may hamper the ability of the local generic medicines' industry to provide cheap drugs to developing countries, reports the Economic Times. The recently created Indo-US working committee on intellectual property rights (IPR) may...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
17
Pharmaceutical Market Forecast
17
Table: Pharmaceutical Sales, Historical Data And Forecasts (India 2010-2018)
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (India 2010-2018)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (India 2010-2018)
22
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (India 2010-2018)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (India 2010-2018)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (India 2010-2018)
27
Generic Drug Market Forecast
28
Table: Generic Drug Market Indicators, Historical Data And Forecasts (India 2010-2018)
29
OTC Medicine Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (India 2010-2018)
31
Pharmaceutical Trade Forecast
32
Table: Pharmaceutical Trade Data And Forecasts (India 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (India 2012-2018)
33
Other Healthcare Data
34
Macroeconomic Forecasts
35
Downgrade Due To Significant Pull-Back In Capital Spending
36
Waning Private Consumption Growth Poses Further Downside Risks
36
Not All Gloom: Data Could Boost BJP's Position
37
Table: India - Economic Activity
38
Industry Risk Reward Ratings
39
Asia Pacific Risk/Reward Ratings
39
India Risk/Reward Ratings
45
Rewards
45
Risks
45
Market Overview
46
Industry Trends And Developments
47
Epidemiology
47
Table: Leading Causes Of Death In India (2008)
48
Healthcare Sector
48
Healthcare Sector Developments
50
Healthcare Insurance
55
Research & Development
56
Table: R&D Expenditure* In Top 20 Indian Pharmaceutical Firms (By Market Capitalisation) (USDmn)
58
Clinical Trials
59
Foreign Direct Investment (FDI)
62
Biosimilars
67
Table: List Of Selected Biosimilars Developed By Indian Pharmaceutical Firms
69
Traditional Medicines
71
Regulatory Development
72
Pharmaceutical Advertising
75
Pharmacovigilance
75
Intellectual Property Regime
76
Table: History Of The Indian Patent System
77
Table: A Series Of Setbacks For Innovative Pharmaceutical Firms
79
Pricing Policy
82
Compulsory Licences
83
Competitive Landscape
85
Pharmaceutical Sector
85
Key Industry Developments
88
Domestic Industry
97
Pharmaceutical Distribution
99
Pharmaceutical Retail Sector
100
Company Profile
101
Dr
101
Cipla
107
Ranbaxy Laboratories
112
Aurobindo Pharmaceutical
119
Pfizer
123
GlaxoSmithKline
128
Novartis
133
Sanofi India
137
Merck & Co
141
Demographic Forecast
145
Table: India's Population By Age Group, 1990-2020 ('000)
146
Table: India's Population By Age Group, 1990-2020 (% of total)
147
Table: India's Key Population Ratios, 1990-2020
148
Table: India's Rural And Urban Population, 1990-2020
148
Glossary
149
Methodology
151
Pharmaceutical Expenditure Forecast Model
151
Healthcare Expenditure Forecast Model
151
Notes On Methodology
152
Risk/Reward Ratings Methodology
153
Ratings Overview
154
Table: Pharmaceutical Risk/Reward Ratings Indicators
154
Indicator Weightings
155

The India Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's India Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Indian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for India to test other views - a key input for successful budgeting and strategic business planning in the Indian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Indian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in India.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc